5438-24-4

Usage

Uses

Used in Organic Synthesis:
5,6-Dimethyl-3a,4,7,7a-tetrahydroisobenzofuran-1,3-dione is used as a building block in organic synthesis for the preparation of various compounds. Its unique structure and reactivity allow for the creation of a wide range of chemical entities, making it a versatile component in the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 5,6-dimethyl-3a,4,7,7a-tetrahydroisobenzofuran-1,3-dione is utilized as a key intermediate in the development of new drugs. Its potential applications in medicinal chemistry and drug discovery are attributed to its distinctive structural features, which can be exploited to design and synthesize novel therapeutic agents with improved pharmacological properties.
Used in Medicinal Chemistry:
5,6-Dimethyl-3a,4,7,7a-tetrahydroisobenzofuran-1,3-dione is employed in medicinal chemistry as a structural motif for the design of bioactive molecules. Its presence in various compounds can contribute to their biological activity, making it a valuable component in the development of new pharmaceuticals with potential therapeutic applications.
Used in Drug Discovery:
In the field of drug discovery, 5,6-dimethyl-3a,4,7,7a-tetrahydroisobenzofuran-1,3-dione serves as a starting point for the identification and optimization of lead compounds. Its unique structural features can be leveraged to explore new chemical space and discover novel drug candidates with improved efficacy and selectivity.
Overall, 5,6-dimethyl-3a,4,7,7a-tetrahydroisobenzofuran-1,3-dione is a versatile and valuable compound in the fields of organic synthesis, pharmaceutical research, medicinal chemistry, and drug discovery, owing to its unique structure, reactivity, and potential applications in the development of new and innovative therapeutic agents.

InChI:InChI=1/C10H12O3/c1-5-3-7-8(4-6(5)2)10(12)13-9(7)11/h7-8H,3-4H2,1-2H3

Upstream product

• 108-31-6 maleic anhydride 
• 513-81-5 2,3-dimethyl-buta-1,3-diene 
• 76-09-5 2,3-dimethyl-2,3-butane diol 

Downstream Products

• 5680-10-4 4,5-dimethylphthalic acid 
• 619-04-5 3,4-dimethylbenzoic acid 
• 870171-40-7 2-(3-fluorophenyl)-5,6-dimethyl-1H-isoindole-1,3(2H)-dione 
• 110568-65-5 2,3-Dihydro-5,6-dimethyl-1H-isoindol-1-on 
• 5999-20-2 4,5-dimethylphthalic anhydride 

Relevant academic research and scientific papers

Hydrogen-bond symmetry in zwitterionic phthalate anions: Symmetry breaking by solvation

The cationic nitrogen of zwitterion 1 is located symmetrically with respect to its intramolecular OHO hydrogen bond. Incorporation of one 18O allows investigation of the H-bond symmetry by the NMR method of isotopic perturbation. In both CDsub

CYCLIC CARBOXYLIC ACID DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ARTHRITIS COMPRISING SAME

The present invention relates to a cyclic carboxylic acid derivative represented by chemical formula 1, or a pharmaceutically acceptable salt, a hydrate or a solvate thereof. The cyclic carboxylic acid derivative has properties of inhibiting aggrecanase,

BISMUTH PERFLUOROALKYLPHOSPHINATES AS LEWIS ACID CATALYSTS

The invention relates to bismuth perfluoroalkylphosphinates as Lewis acid catalysts, the compounds, and processes for the preparation thereof. [in-line-formulae]ArxBi[OP(O)(Rf)2]3-x??(Ia),[/in-line-formulae] [in-line-formulae]Ar3Bi[OP(O)(Rf)2]2??(Ib).[/in-line-formulae]

Sustainable production of pyromellitic acid with pinacol and diethyl maleate

Herein, we report an unprecedented and sustainable route to synthesize pyromellitic acid (PMA), a monomer of polyimide, with pinacol and diethyl maleate which can be derived from lignocellulose. Analogously, a sustainable route to trimellitic acid (TMA) was also developed using pinacol and acrylate as the feedstocks.

Bismuth Perfluoroalkylphosphinates: New Catalysts for Application in Organic Syntheses

Commercially available BiPh3was treated with perfluoroalkylphosphinic acids [for example, (C2F5)2P(O)OH] to generate novel, highly Lewis acidic bismuth(III) perfluoroalkylphosphinates of the type PhxBi[RF2PO2]3?x(x=0, 1, 2) (RF=-C2F5, -C4F9). The first bismuth(V) perfluoroalkylphosphinate, Ph3Bi[(C2F5)2PO2]2, was synthesized from Ph3BiCl2and Ag[(C2F5)2PO2]. Examples for the successful application of the catalytically active bismuth(III) and bismuth(V) phosphinates in carbon–carbon bond forming reactions, such as Friedel–Crafts acylation and alkylation, Diels–Alder, Strecker and Mannich reaction, are presented.

Pentacenequinone-stabilized silver nanoparticles: A reusable catalyst for the diels-alder [4 + 2] cycloaddition reactions

Silver nanoparticles (AgNPs) stabilized by aggregates of derivative 4 have been used as catalyst for the construction of synthetically and biologically important [4 + 2] cycloadducts at room temperature.

Solvent-free Diels-Alder reaction in a closed batch system

Solvent-free Diels-Alder reactions were carried out by heating a mixture of a volatile diene, such as 1,3-butadiene, isoprene, or 2,3-dimethyl-1,3- butadiene, and a dienophile, such as methyl vinyl ketone, methyl acrylate, or maleic anhydride, in a closed batch reactor. High yields of Diels-Alder products were obtained without using solvents and catalysts within a short reaction time in most of the reactions. In particular, several reactions of dienophiles with 1,3-butadiene, which is known as a diene with low reactivity because of its gaseous form, also proceeded with high yields of Diels-Alder products in the closed batch reactor under conditions pressured by the reactant vapor. Solvent-free reactions provided high yields compared to reactions in solvent since the reaction heat directly resulted in increasing the reaction temperature and pressure. Energy in the exothermic reaction was used effectively in the closed batch system under solvent-free conditions.

Synthesis and physicochemical properties of strong electron acceptor 14,14,15,15-tetracyano-6,13-pentacenequinodimethane (TCPQ) diimide

14,14,15,15-Tetracyano-6,13-pentacenequinodimethane (TCPQ) diimide, a new tetracyanoquinodimethane analogue with extended conjugation and imide substituents, was synthesized by double Diels-Alder reactions and a Knoevenagel condensation reaction. Experimental results showed that TCPQ diimide has a low LUMO energy level (-4.03 eV) and good solubility in organic solvents.

A Tin-tungsten mixed oxide as an efficient heterogeneous catalyst for C-C Bond Bond-Forming reactions

The tin-tungsten mixed oxide prepared by the calcination of the tin-tungsten hydroxide precursor with a Sn/W molar ratio of 2 at 800 °C (SnW2-800) acts as an effective and reusable solid catalyst for C-C bond-forming reactions, such as the cyclization of citronellal, the Diels-Alder reaction, and the cyanosilylation of carbonyl compounds with trimethylsilyl cyanide (TMSCN). Various kinds of structurally diverse aliphatic, aromatic, and unsaturated, heteroatom-containing substrates could be converted into the desired products in high to excellent yields. The observed catalyses for these reactions were truly heterogeneous and the recovered catalyst could be reused several times without an appreciable loss of its high catalytic performance. The Bronsted acid sites generated on the aggregated polytungstate species on SnW2-800 likely play an important role in the C-C bond-forming reactions.

Novel water-soluble sedative-hypnotic agents: Isoindolin-1-one derivatives

We developed new intravenous sedative-hypnotic compounds with the isoindolin-1-one skeleton focusing on the water-soluble property and in vivo safety. We synthesized approximately 170 derivatives and evaluated their hypnotic effects by intravenous administration of the compounds to mice. A series of the 2-phenyl-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]isoindolin-1-one analogs, 3(-), 5(-), 27(-), and 47(-) [JM-1232(-)], showed potent sedative-hypnotic activity with good water solubility and a wide safety margin. The hypnotic doses (HD50s) of these 4 compounds when administered to mice were 2.35, 1.90, 2.17, and 3.12 mg/kg, respectively, and the lethal doses (LD50s) were 88.67, 64.69, >120, and >120 mg/kg, respectively. The therapeutic indexes (LD50/HD50) were 37.73, 34.05, >55.30, and >38.46, respectively. Among these compound, 47(-) [JM-1232(-)] is being considered as the most potential candidate for clinical trials in humans.